{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United Kingdom Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/gb/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/gb/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from United Kingdom, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:2ce674b337483eaa8cdb7407eb2350e4630b953f63dafef1c2bbd3a4558cba28", "url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "external_url": "https://finance.yahoo.com/healthcare/articles/astrazeneca-lse-azn-signs-two-151237153.html", "title": "AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven tools are changing drug discovery and cancer care, it is worth looking more broadly at the companies building these capabilities through 6 healthcare AI stocksLSE:AZN Earnings & Revenue Growth as at Aug 2026 AstraZeneca sits among the large global pharmaceutical companies with a strong focus on oncology, so investors often watch how new partnerships align with that core specialty. The stock trades at \u00a3118.96 and has been volatile recently, with the share price down over the past week and month, yet still showing gains over the past year and over multi year periods. Beyond the headline: 2 risks and 4 things going right for AstraZeneca that every investor should see. How does this SOPHiA GENETICS deal actually change things for AstraZeneca? The agreement gives AstraZeneca access to SOPHiA GENETICS's decentralized Solid Tumor and Hematological Oncology diagnostic platforms for use as companion diagnostics. That links AstraZeneca's oncology drugs directly to assays that can run in a wider range of hospitals, not only in central labs. For AstraZeneca, this can support uptake of existing and future cancer therapies where treatment decisions rely on accurate biomarker testing, and it ties real world data generation more tightly to its portfolio. What does this mean for the AstraZeneca oncology Narrative? The Narrative around AstraZeneca centers on oncology approvals, late stage assets such as Datroway and Sone Ve, and use of data and technology to support precision medicine. Partnering with SOPHiA GENETICS fits that story by building the diagnostic side needed for targeted drugs to reach the right patients. It also sits alongside other alliances like Pathos AI, reinforcing a pattern of AstraZeneca using external platforms to support its R&D and commercial ambitions rather than relying only on internal tools. What should investors watch next from this diagnostics partnership? The key marker will be when the first SOPHiA based companion diagnostic linked to an AstraZeneca therapy is validated and cleared by regulators in a major market such as the US or EU. Concrete updates on regulatory submissions, specific cancer indications covered, and uptake of decentralized assays in clinical trial settings will show whether this collaboration is translating into broader real world use of AstraZeneca's oncology drugs. Story Continues For the full picture including more risks and rewards, check out the complete AstraZeneca analysis. Alternatively, you can check out the community page for AstraZeneca to see how other investors believe this latest news will impact the company's narrative. Do you think there's more to the story for AstraZeneca? Head over to our Community to see what others are saying! This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AZN.L. Have feedback on this ", "date_published": "2026-08-08T15:12:37+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AZN"], "_sharemaestro": {"country": "United Kingdom", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AZN", "name": "AstraZeneca PLC", "sentiment_url": "https://sharemaestro.com/sentiment/a8a1958e-2ccb-4df7-bc10-bc89c0a4f6e7/"}]}}]}